These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 24345268)

  • 1. The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia.
    Gill KM; Grace AA
    Curr Pharm Des; 2014; 20(31):5069-76. PubMed ID: 24345268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia.
    Gill KM; Lodge DJ; Cook JM; Aras S; Grace AA
    Neuropsychopharmacology; 2011 Aug; 36(9):1903-11. PubMed ID: 21562483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The attentional set-shifting test paradigm in rats for the screening of novel pro-cognitive compounds with relevance for cognitive deficits in schizophrenia.
    Denis Goetghebeur PJ; Dias R
    Curr Pharm Des; 2014; 20(31):5060-8. PubMed ID: 24345267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.
    Xu MY; Wong AHC
    Acta Pharmacol Sin; 2018 May; 39(5):733-753. PubMed ID: 29565038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hippocampal GABA
    Neugebauer NM; Miyauchi M; Sato T; Tadano J; Akal H; Ardehali H; Meltzer HY
    Behav Brain Res; 2018 Apr; 342():11-18. PubMed ID: 29289597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine, the prefrontal cortex and schizophrenia.
    Knable MB; Weinberger DR
    J Psychopharmacol; 1997; 11(2):123-31. PubMed ID: 9208376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral effects of the benzodiazepine-positive allosteric modulator SH-053-2'F-S-CH₃ in an immune-mediated neurodevelopmental disruption model.
    Richetto J; Labouesse MA; Poe MM; Cook JM; Grace AA; Riva MA; Meyer U
    Int J Neuropsychopharmacol; 2015 Jan; 18(4):. PubMed ID: 25636893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.
    Boggs DL; Carlson J; Cortes-Briones J; Krystal JH; D'Souza DC
    Curr Pharm Des; 2014; 20(31):5077-92. PubMed ID: 24345265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of cognitive impairment in schizophrenia.
    Goff DC; Hill M; Barch D
    Pharmacol Biochem Behav; 2011 Aug; 99(2):245-53. PubMed ID: 21115035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Effect of Dopamine D4 Receptor Activation on Low-Frequency Oscillations in the Prefrontal Cortex and Hippocampus May Bias the Bidirectional Prefrontal-Hippocampal Coupling.
    Thörn CW; Kafetzopoulos V; Kocsis B
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia.
    Menzies L; Ooi C; Kamath S; Suckling J; McKenna P; Fletcher P; Bullmore E; Stephenson C
    Arch Gen Psychiatry; 2007 Feb; 64(2):156-67. PubMed ID: 17283283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin 5-HT
    Gener T; Tauste Campo A; Alemany-González M; Nebot P; Delgado-Sallent C; Chanovas J; Puig MV
    Neuropharmacology; 2019 Nov; 158():107743. PubMed ID: 31430459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
    Beinat C; Banister SD; Herrera M; Law V; Kassiou M
    CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Converging models of schizophrenia--Network alterations of prefrontal cortex underlying cognitive impairments.
    Sakurai T; Gamo NJ; Hikida T; Kim SH; Murai T; Tomoda T; Sawa A
    Prog Neurobiol; 2015 Nov; 134():178-201. PubMed ID: 26408506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Current pro-cognitive therapeutic strategies for improved pharmacological treatment in schizophrenia.
    Wadenberg ML
    Curr Pharm Des; 2014; 20(31):5045. PubMed ID: 24345264
    [No Abstract]   [Full Text] [Related]  

  • 17. Amelioration of cognitive impairments induced by GABA hypofunction in the male rat prefrontal cortex by direct and indirect dopamine D
    Auger ML; Meccia J; Phillips AG; Floresco SB
    Neuropharmacology; 2020 Jan; 162():107844. PubMed ID: 31704272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive deficits caused by prefrontal cortical and hippocampal neural disinhibition.
    Bast T; Pezze M; McGarrity S
    Br J Pharmacol; 2017 Oct; 174(19):3211-3225. PubMed ID: 28477384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.
    Redrobe JP; Elster L; Frederiksen K; Bundgaard C; de Jong IE; Smith GP; Bruun AT; Larsen PH; Didriksen M
    Psychopharmacology (Berl); 2012 Jun; 221(3):451-68. PubMed ID: 22124672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management.
    Fone KCF; Watson DJG; Billiras RI; Sicard DI; Dekeyne A; Rivet JM; Gobert A; Millan MJ
    Mol Neurobiol; 2020 May; 57(5):2144-2166. PubMed ID: 31960362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.